First experience with biosimilar infliximab CT-P13 in patients with inflammatory rheumatic diseases in the Czech Republic in the ATTRA national registry

Czech version

Authors: K. Pavelka ¹; K. Jarošová ¹; D. Suchý ²; M. Uher ³; K. Hejduk ³
Authors‘ workplace: Revmatologický ústav Praha ¹; Oddělení klinické farmakologie Fakultní nemocnice Plzeň ²; Institut biostatistiky a analýz, Lékařská fakulta, Masarykova univerzita Brno ³
Published in: Čes. Revmatol., 24, 2016, No. 1, p. 15-30.
Category: Original article

Overview

Biosimilar infliximab CT-P13, developed by Korean company Celltrion, is the first EMA approved biosimilar agent. In double-blind studies in rheumatoid arthritis and ankylosing spondylitis biosimilar infliximab was equally effective and had the same safety profile as the original infliximab.

CT-P13 was introduced into clinical practice in the Czech Republic at the end of 2013. All the patients have been treated according to the indications of the Czech Society for Rheumatology at the centers of biological treatment and enrolled in the ATTRA registry. The aim of this study was to evaluate the first year of experience with the CT-P13 agent in the ATTRA national registry.

Results:
A total of 100 patients with rheumatoid arthritis (RA) were enrolled in the registry. Analysis was then performed on 93 adult patients. The mean age of these patients was 54 years and the disease duration was 10 years. Disease activity was high, the average baseline DAS 28 was 5.7 ± 0.8, number of swollen joints was 8.8 ± 4.3 and CRP levels were 28.1 ± 22.5 mg / l. After nine months of treatment there was a significant decrease in all monitored parameters. At the start of treatment 73.3% of patients had high disease activity according to EULAR and 26.7% of patients had moderate activity. After nine months of treatment 87.5% of patients were in remission, 93.7% had low activity, 6.3% had moderate activity, and none of the patients had high disease activity. The treatment survival after nine months was 78.0%.

Seventy-two patients were enrolled in the registry of ankylosing spondylitis (AS) and 68 adult patients thereof were further analyzed. Their average age was 44 years and disease duration of 9 years. Disease activity at the start of treatment was high, and the average BASDAI was 6.2 ± 1.7 and CRP levels were 31.1 ± 26.7 mg / l. After nine months of treatment BASDAI decreased to 0.9 ± 1.4, and quality of life improved (HAQ decreased from 1.1 ± 0.6 to 0.4 ± 0.5). There were improvements in all dimensions of quality of life according to SF-36.

In the group of RA patients 21 adverse events and 7 serious adverse events were reported. In patients with AS there were 7 adverse events and no serious adverse event. No new signals of toxicity were reported.

Conclusion:
First experience with biosimilar CT-P13 in the ATTRA national registry is positive. No new signals of toxicity were reported.

Key words:
Biosimilar infliximab CT-P13, inflammatory rheumatic diseases

Sources

1. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93.

2. Nam JL, Winthrop KL, van Vollenhoven R, et al. Current evidence for management of rheumatoid arthritis with biological disease – modifying antirheumatic drugs: a systematic literature review inform in the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976–986.

3. Závada J, Uher M, Jarkovský J, et al. Hodnocení skóre užitku EW-5D a odhad nákladové užitečnosti prvního roku léčby inhibitory TNF u pacientů s revmatoidní artritidou – výsledky analýzy z národního registru biologické léčby ATTRA. Čes Revmatol 2014; 22: 10–16.

4. World Health Organization, Guidelines on evaluation of similar biotherapeutic products (SBPs), 2009. http://wwwwho.int/biologicals/areas/biological- therapeutics/BIOTHERAPEUTICS-FOR WEB.22APRIL 2010.pdf, Accessed 19 Dec 2013

5. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology – derived proteins as active substance: non clinical and clinical issues. Draft: 2013.http//www.ema.europa.eu/docs/en-GB/document-library ESPAR-Public assessment- report/human/ 002778/WC50 0151490.pdf Accessed 17 Febr 2014

6. McKeage K: A review of CT-P13: An infliximab biosimilar. BioDrugs. 2014 DOI 10.1007/s 40259-014-0094-1

7. Park W, Hrycaj P, Jeka BS, et al. A randomised, double blind, multicentre, parallel-group, prospective study comparing the pharmacocinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The Planetas study. Ann Rheum Dis 2013; 72: 1605–12.

8. Park W, Jaworski J, Brzeziecki J, et al. A randomised, double blind, paralel – group, phase 1 study comparing the pharmacokinetics safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 weeks results from the PLANETAS study. Arthritis Rheum 2013; 72 (Suppl.3): 516.

9. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double blind, parallel - group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613–1620.

10. Yoo DH, Racewicz A, Brzeziecki J, et al. A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Ann Rheum Dis 2013; 65(Suppl.3): 73.

11. Pavelka K, Gatterová J, Tegzová D, Jarošová K, et al. Radiographic progression in RA patients treated with infliximab, data from the Czech national registry (ATTRA). Clin Exp Rheum 2007; 25: 540–545.

12. Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritídy. Čes Revmatol 2010; 18: 182–191.

13. Vencovský J., et al. Bezpečnost biologické léčby – doporučení České revmatologické společnosti. Čes Revmatol 2009; 3: 146–160.

14. Kim JS, Hong JA, Kudrin A. 5 year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. Arthritis Rheum 2014; 66 (Suppl): 512.

Labels

Dermatology & STDs Paediatric rheumatology Rheumatology

Hematological manifestations in patients with systemic lupus erythematosus

Article was published in

Czech Rheumatology

2016 Issue 1